| XLS |
|
|
|
|
|
|
|
|
|
|
Investments in |
Securities |
Loans and other noncurrent financial assets |
Total | ||
|
€ million |
available-for-sale |
available-for- |
available-for-sale financial investments |
financial investments held to maturity | ||
|
Book value January 1, 2010 |
79.4 |
22.0 |
1.0 |
– |
16.0 |
118.4 |
|
Currency translation |
– |
– |
– |
– |
0.2 |
0.2 |
|
Changes in scope of consolidation |
– |
–4,419.8 |
– |
– |
– |
–4,419.8 |
|
Additions |
9.2 |
4,628.0 |
6.8 |
|
22.4 |
4,666.4 |
|
Impairment losses |
– |
– |
– |
– |
– |
– |
|
Disposals |
–15.2 |
–201.7 |
–0.3 |
– |
–4.1 |
–221.3 |
|
Fair value adjustments of long-term investments taken directly to equity |
–13.6 |
– |
– |
– |
– |
–13.6 |
|
Transfers |
1.1 |
–1.1 |
– |
– |
– |
– |
|
Book value December 31, 2010 |
60.9 |
27.4 |
7.5 |
– |
34.5 |
130.3 |
|
|
|
|
|
|
|
|
|
Book value January 1, 2011 |
60.9 |
27.4 |
7.5 |
– |
34.5 |
130.3 |
|
Currency translation |
– |
– |
– |
– |
– |
– |
|
Changes in scope of consolidation |
– |
92.7 |
– |
– |
– |
92.7 |
|
Additions |
12.9 |
150.0 |
– |
– |
5.2 |
168.1 |
|
Impairment losses |
–14.9 |
– |
– |
– |
– |
–14.9 |
|
Disposals |
–39.3 |
–257.7 |
–0.7 |
– |
–21.0 |
–318.7 |
|
Fair value adjustments of long-term investments taken directly to equity |
2.5 |
– |
– |
– |
0.3 |
2.8 |
|
Transfers |
– |
– |
– |
– |
– |
– |
|
Book value December 31, 2011 |
22.1 |
12.4 |
6.8 |
– |
19.0 |
60.3 |
As of December 31, 2011, the book value of non-current financial assets amounting to € 60.3 million included non-current financial assets available-for-sale (investments) with a book value of € 32.6 million (2010: € 57.2 million) that were carried at cost since fair value could not be reliably determined.
Changes in the scope of consolidation totaling € 92.7 million include first-time consolidations of € 164.9 million (2010: € 4,612.6 million) and deconsolidations of € 257.6 million (2010: € 192.8 million). The first-time consolidations relate almost exclusively to the acquisition of the microbiology business of Biotest AG as well as Amnis Corporation, Seattle, WA (USA), and the first-time consolidation of Beijing Skywing Technology Co. Ltd., Beijing, China. The deconsolidations relate to Merck Capital Asset Management, Malta, as well as the divestments of our Crop BioScience business and Serono Contracting Ltd., United Kingdom. A detailed presentation of this item can be found under “Scope of consolidation”.
The following unrealized gains and losses arising from non-current financial assets classified as available-for-sale were recognized in equity as of the balance sheet date:
| XLS |
|
|
|
|
|
|
|
|
|
€ million |
Available-for-sale investments |
Available-for-sale securities |
Total |
Available-for-sale investments |
Available-for-sale securities |
Total |
|
Fair values/Book values |
34.5 |
6.8 |
41.3 |
88.3 |
7.5 |
95.8 |
|
Amortized acquisition cost |
34.2 |
6.8 |
41.0 |
90.5 |
7.5 |
98.0 |
|
Unrealized gains/losses |
0.3 |
– |
0.3 |
–2.2 |
– |
–2.2 |